Make your money go further for just 25p per day

Bioventix (AIM:BVXP) record results from this unusual high margin offering

05/10/2015 · Bioventix PLC (BVXP) 

The developer of high-affinity monoclonal antibodies for applications in clinical diagnostics, announced fantastic audited results for the year ended 30 June 2015. Pre-tax margins of over 70% and superb cash generation highlight the unusual (yet highly attractive) nature of this small business

We published a detailed commentary on this back in April 2015 which is worth a read.

For the year to 30th June 2015 revenue was up 23% to £4.3m and pre-tax profit up 39% to £3.1m (2013/14: £2.2m). The operating cash inflow was also a majestic £2.915m with free cash flow £2m after a modest £113k of capex. Year-end cash was £4.13m after the payment of equity…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

Have your say

Log in or register to view or add comments.

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Bioventix PLC

Bonkers Bargain soars on takeover - more to go for?

29/03/2021 · Company Insights

Shares in an earlier Bonkers Bargain soar on a takeover approach, but there appears to be…


Coronavirus impact: 19 Oct - boohoo tumbles (again) but others impress

19/10/2020 · Company Insights

While boohoo’s travails continue to dominate the news on AIM, several other fast-growing companies covered here…


More Company Insights

Bonkers Bargain: Superdry is looking much more promising

06/05/2021 · Superdry

ESG financing facility first of many

​Stonking Small Caps: disrupting an aged profession

06/05/2021